Soluble TWEAK level: Is it a marker for cardiovascular disease in long-term hemodialysis patients?

Journal of Nephrology

Volumn 26, Issue 1, 2013, Pages 136-143

  Gungor, Ozkan ^a   Kircelli, Fatih ^a   Asci, Gulay ^a   Carrero, Juan Jesus ^b   Tatar, Erhan ^a   Demirci, Meltem Sezis ^a   Özbek, Süreyya Süha ^a   Ceylan, Naim ^a   Toz, Huseyin ^a   Ozkahya, Mehmet ^a   Ok, Ercan ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Arterial stiffness; Atherosclerosis; Coronary calcification; Dialysis; sTWEAK

Indexed keywords

MEMBRANE PROTEIN; SOLUBLE TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ADULT; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PULSE WAVE;

AGED; ANALYSIS OF VARIANCE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CAROTID INTIMA-MEDIA THICKNESS; CORONARY VESSELS; FEMALE; HUMANS; MALE; MIDDLE AGED; PULSE WAVE ANALYSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TUMOR NECROSIS FACTORS; VASCULAR CALCIFICATION; VASCULAR STIFFNESS;

EID: 84872450180     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000121     Document Type: Article

References (39)

1. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008;3(2):505-521.
2. Shoji T, Maekawa K, Emoto M, et al. Arterial stiffness predicts cardiovascular death independent of arterial thickness in a cohort of hemodialysis patients. Atherosclerosis. 2010; 210(1):145-149.
3. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant. 2002;17(10):1713-1724.
4. Kurnatowska I, Grzelak P, Stefańczyk L, Nowicki M. Tight relations between coronary calcification and atherosclerotic lesions in the carotid artery in chronic dialysis patients. Nephrology (Carlton). 2010;15(2):184-189.
5. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/ Fn14 receptor. Cytokine Growth Factor Rev. 2003;14(3-4): 241-249.
6. Gao HX, Campbell SR, Burkly LC, et al. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine. 2009;46(1):24-35.
7. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine. 2007;40(1):1-16.
8. Jakubowski A, Browning B, Lukashev M, et al. Dual role for TWEAK in angiogenic regulation. J Cell Sci. 2002;115(Pt 2): 267-274.
9. Blanco-Colio LM, Martín-Ventura JL, Munoz-Garcia B, et al. TWEAK and Fn14: new players in the pathogenesis of atherosclerosis. Front Biosci. 2007;12(8-12):3648-3655.
10. Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2007; 27(4):916-922.
11. Yilmaz MI, Sonmez A, Ortiz A, et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol. 2011;6(4):785-792.
12. Carrero JJ, Ortiz A, Qureshi AR, et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(1):110-118.
13. Perper SJ, Browning B, Burkly LC, et al. TWEAK is a novel arthritogenic mediator. J Immunol. 2006;177(4):2610-2620.
14. Vincent C, Findlay DM, Welldon KJ, et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res. 2009;24(8):1434-1449.
15. Ando T, Ichikawa J, Wako M, et al. TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cells. Arthritis Res Ther. 2006;8(5):R146.
16. Williams SA, Martin SK, Vincent C, et al. Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. Br J Haematol. 2010;150(3):373-376.
17. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15(4):827-832.
18. Guérin AP, Pannier B, Métivier F, Marchais SJ, London GM. Assessment and significance of arterial stiffness in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17(6):635-641.
19. Yilmaz MI, Carrero JJ, Ortiz A, et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(11):1716-1723.
20. Chorianopoulos E, Rosenberg M, Zugck C, Wolf J, Katus HA, Frey N. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail. 2009;11(11):1050-1056.
21. Jain M, Jakubowski A, Cui L, et al. A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation. 2009;119(15):2058-2068.
22. Chicheportiche Y, Chicheportiche R, Sizing I, et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res. 2002;4(2):126-133.
23. Kralisch S, Ziegelmeier M, Bachmann A, et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis. 2008;199(2):440-444.
24. Maecker H, Varfolomeev E, Kischkel F, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell. 2005;123(5):931-944.
25. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis. 2010;211(1):322-326.
26. Inta I, Frauenknecht K, Dörr H, et al. Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke. J Neurol Sci. 2008;275(1-2):117-120.
27. Muñoz-García B, Moreno JA, López-Franco O, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 2009;29(12):2061-2068.
28. Justo P, Sanz AB, Sanchez-Niño MD, et al. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int. 2006;70(10):1750-1758.
29. Sanz AB, Sanchez-Niño MD, Izquierdo MC, et al. Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med. 2009;13(9B):3329-3342.
30. Muñoz-García B, Martín-Ventura JL, Martínez E, et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke. 2006;37(8):2044-2053.
31. Carrero JJ, Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol. 2009;4(Suppl 1):S49-S55.
32. Shioi A, Mori K, Jono S, et al. Mechanism of atherosclerotic calcification. Z Kardiol. 2000;89(14)(Suppl 2):75-79.
33. Boström KI. Cell differentiation in vascular calcification. Z Kardiol. 2000;89(14)(Suppl 2):69-74.
34. Shanahan CM, Proudfoot D, Tyson KL, Cary NR, Edmonds M, Weissberg PL. Expression of mineralisation-regulating proteins in association with human vascular calcification. Z Kardiol. 2000;89(14)(Suppl 2):63-68.
35. Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem. 2003;278(34):32317-32323.
36. Coen G, De Paolis P, Ballanti P, et al. Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23. J Nephrol. 2011;24(3):313-321.
37. Rezg R, Barreto FC, Barreto DV, Liabeuf S, Drüeke TB, Massy ZA. Inhibitors of vascular calcification as potential therapeutic targets. J Nephrol. 2011;24(4):416-427.
38. Coll B, Betriu A, Martínez-Alonso M, et al. Large artery calcification on dialysis patients is located in the intima and related to atherosclerosis. Clin J Am Soc Nephrol. 2011;6(2):303-310.
39. Asci G, Ok E, Savas R, et al. The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transplant. 2011;26(3):1010-1015.